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Purpose of the study
To evaluate long-term outcomes in pts maintaining a
NVP-based regimen.
Methods
Retrospective cohort study. Pts received a NVP regimen
for at least 5 years and continued up to present. Demo-
graphic, clinical, and analytical variables were recorded.
A sample size of 506 pts was randomly selected from
participating cohorts.
Summary of results
Median follow up 8.9 (5.7-11.3) years (506 pts followed
≥6 years and 270 ≥ 9 years). At baseline: 74% men, 47
years old, 36% drug users, 40% AIDS, 40% HCV+, 14%
alcohol. 45% detectable VL, CD4 395/uL, 19% CD4 <
200/uL, 27% ALT Grade 1-2, 36% AST grade 1-2. 30%
ART naïve. 84% received NVP+2 nucleosides (NRTI)
during the study period, 17% PI.
Most frequent current combinations were NVP+TDF/
FTC in 31%, +ABC/3TC in 24% and +ZDV/3TC in
22%. 97% reached undetectable VL. In pts receiving 2
NRTI+NVP (n=423), regardless of being HCV+ or -, a
significant increase was observed in general health status
markers: hemoglobin, platelets and albumin (all
p<0.001), and +218 and +322 CD4 cells increase after 6
and 9 years (p<0.001). Triglyceride levels decreased 19%
and total cholesterol 4% in pretreated pts vs 9% and
12% increase in naive pts. After 6 years, the proportion
of pts with lipid levels above (below in HDL) the NCEP
thresholds for recommending lipid lowering therapy was
50% for TC, 43% TG, 34% LDL and 14% HDL.
Regarding liver outcomes in the 506 pts, a significant
decrease in ALT and AST levels were found in naive
(p=0.02, p<0.001) and HCV+ pts (p=0.065, p<0.001),
while a strong decrease in alkaline phosphatase (AP)
levels (up to -44%) was observed in naive and pretreated
p t sa sw e l la si nH C V +o r— (all p<0.001), regardless of
TDF use. GGT levels increased by 78% regardless of the
patient status (p<0.001).
This favourable changes in liver function tests
occurred despite 53% of 89 pts in whom biopsy or
fibroscan was performed after a median of 7.1 years of
NVP therapy, fibrosis (≥ F2 and/or 7≥kPa) was detected.
In addition, as a consequence of transaminase and plate-
let changes, Fib-4 index significantly decreased in ARV
naive HIV/HCV pts at 9 years (p=0.01).
Conclusions
Patients receiving a long-term NVP-including regimen,
show a progressive improvement in general health status
and CD4 response, an acceptable lipid profile and
favourable changes in liver function tests, even in those
with HCV+. The marked decrease in AP levels shown in
this large cohort of NVP-treated pts merits further
study.
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